Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Non-Current Debt (2018 - 2024)

Serina Therapeutics' Non-Current Debt history spans 7 years, with the latest figure at $693000.0 for Q3 2024.

  • For Q3 2024, Non-Current Debt changed 0.0% year-over-year to $693000.0; the TTM value through Sep 2024 reached $693000.0, changed 0.0%, while the annual FY2022 figure was $10.5 million, 72.85% up from the prior year.
  • Non-Current Debt for Q3 2024 was $693000.0 at Serina Therapeutics, roughly flat from $693000.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $10.5 million in Q4 2022 and bottomed at $693000.0 in Q3 2023.
  • The 5-year median for Non-Current Debt is $5.3 million (2021), against an average of $4.9 million.
  • The largest annual shift saw Non-Current Debt surged 1520.42% in 2020 before it crashed 93.12% in 2024.
  • A 5-year view of Non-Current Debt shows it stood at $3.9 million in 2020, then surged by 55.44% to $6.1 million in 2021, then surged by 72.85% to $10.5 million in 2022, then tumbled by 93.39% to $693000.0 in 2023, then changed by 0.0% to $693000.0 in 2024.
  • Per Business Quant, the three most recent readings for SER's Non-Current Debt are $693000.0 (Q3 2024), $693000.0 (Q2 2024), and $693000.0 (Q1 2024).